Evidence map›Paper›PMID 41636852›Full record

ArticleArchives of gynecology and obstetrics2026

Impact of chemotherapy dose capping on treatment intensity and survival in early breast cancer patients with high body surface area.

A Englisch, K Eissler, D Dannehl, J Englisch, A D Hartkopf, S Y Brucker, E M Grischke, L L Volmer, T Engler

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Archives of gynecology and obstetrics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

A Englisch *Department of Women's Health, Tuebingen University, 72076, Tuebingen, Germany. alexander.englisch@med.uni-tuebingen.de.
K Eissler *Department of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
D DannehlDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
J EnglischDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
A D HartkopfDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
S Y BruckerDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
E M GrischkeDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
L L VolmerDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.
T EnglerDepartment of Women's Health, Tuebingen University, 72076, Tuebingen, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeThis study evaluates treatment intensity, tolerability, and survival outcomes in early breast cancer patients with high body surface area (BSA) receiving capped chemotherapy doses.

methodsWe retrospectively analyzed 730 patients with early breast cancer who received neoadjuvant or adjuvant chemotherapy with anthracycline/cyclophosphamide and taxane-based regimens at the University Hospital Tübingen between 2014 and 2021. Institutional policy capped dosing at BSA 2.0 m

resultsAmong 730 patients, 61 (8.4%) had BSA > 2.1 m

conclusionsIn this cohort with consistent dose capping at BSA 2.0 m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsBody Surface AreaBreast NeoplasmsAdultAgedAnthracyclinesBridged-Ring CompoundsChemotherapy, AdjuvantCyclophosphamideDose-Response Relationship, DrugFemaleHumansKaplan-Meier EstimateMiddle AgedNeoadjuvant TherapyProportional Hazards ModelsAnthracyclinesBridged-Ring CompoundsCyclophosphamidetaxaneTaxoidsAnthracycline-taxane chemotherapyDose cappingEarly breast cancerObesityRelative dose intensity

Identifiers

PMID41636852
PMCPMC12872629

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.